Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema).[5][6] It is a Janus kinase inhibitor and it was developed by Pfizer.[5][6] It is taken by mouth.[5]
The most common side effects include nausea (feeling sick), headache, acne, herpes simplex (viral infection of the mouth or the genitals), increased levels of creatine phosphokinase in the blood (an enzyme released into the blood when muscle is damaged), vomiting, dizziness and pain in the upper belly.[6]
Abrocitinib was approved for medical use in the European Union in December 2021,[6] and in the United States in January 2022.[7][8]
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^"Cibinqo Product information". Health Canada. 25 April 2012. Archived from the original on 10 December 2022. Retrieved 30 September 2022.
^"Summary Basis of Decision – Cibinqo". Health Canada. 23 October 2014. Archived from the original on 24 February 2023. Retrieved 23 February 2023.
^"Details for: Cibinqo". Health Canada. 29 September 2022. Retrieved 3 March 2024.
^ abcd"Cibinqo- abrocitinib tablet, film coated". DailyMed. 15 February 2022. Archived from the original on 3 March 2022. Retrieved 3 March 2022.
^ abcde"Cibinqo EPAR". European Medicines Agency (EMA). 11 October 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^"Drug Approval Package: Cibinqo". U.S. Food and Drug Administration (FDA). 10 February 2022. Archived from the original on 10 February 2023. Retrieved 10 February 2023.
^"Drug Trials Snapshot: Cibinqo". U.S. Food and Drug Administration (FDA). 7 June 2023. Retrieved 12 June 2023. This article incorporates text from this source, which is in the public domain.
Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and...
European Medicines Agency (EMA) recommends that the Janus kinase inhibitors abrocitinib, filgotinib, baricitinib, upadacitinib, and tofacitinib should be used...
was declined due to manufacturing issues. Some JAK inhibitors such as abrocitinib, trade name Cibinqo, and upadacitinib, trade name Rinvoq, have been approved...
Global Information
This article incorporates text from this source, which is in the public domain.
